Page last updated: 2024-11-10

hyperoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

quercetin 3-O-beta-D-galactopyranoside : A quercetin O-glycoside that is quercetin with a beta-D-galactosyl residue attached at position 3. Isolated from Artemisia capillaris, it exhibits hepatoprotective activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
ArtemisiagenusA plant genus of the family ASTERACEAE with strong-smelling foliage. It is a source of SANTONIN and other cytotoxic TERPENES.[MeSH]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Artemisia capillarisspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID5281643
CHEMBL ID251254
CHEBI ID67486
SCHEMBL ID1250514
MeSH IDM0075997

Synonyms (83)

Synonym
BIDD:PXR0057
quercetin 3-o-beta-d-galactopyranoside
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(beta-d-galactopyranosyloxy)-5,7-dihydroxy-
quercetin 3-beta-d-galactopyranoside
nsc 407304
quercetin galactoside
einecs 207-580-6
2-(3,4-dihydroxyphenyl)-3-(beta-d-galactopyranosyloxy)-5,7-dihydroxy-4h-1-benzopyran-4-one
quercetin-3-galactoside
ACON1_000623
hyperoside
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3-(.beta.-d-galactopyranosyloxy)-5,7-dihydroxy-
p hyperin
quercetin-3-o-galactoside
hyperozide
hyperosid
hyperasid
quercetin 3-o-.beta.-d-galactopyranoside
quercetin 3-.beta.-d-galactopyranoside
482-36-0
quercetin 3-galactoside
hyperin
MLS000759538
smr000466394
MEGXP0_000392
quercetin 3-d-galactoside, >=97.0% (hplc)
HMS2051H17
2-(3,4-dihydroxy-phenyl)-5,7-dihydroxy-3-((2s,4r,5r)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-chromen-4-one
quercetin 3-o-galactoside
bdbm50241367
CHEMBL251254 ,
chebi:67486 ,
BRD-K84955386-001-01-1
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4h-chromen-3-yl beta-d-galactopyranoside
CCG-100970
8o1cr18l82 ,
ccris 9339
unii-8o1cr18l82
quercetin 3-d-galactoside
AKOS015896780
S5453
AB00639910-03
NC00220
hyperoside [usp-rs]
2-(3,4-dihydroxyphenyl)-3-(.beta.-d-galactopyranosyloxy)-5,7-dihydroxy-4h-1-benzopyran-4-one
quercetin 3-o-.beta.-d-galactoside
hyperoside (constituent of st. john's wort) [dsc]
SCHEMBL1250514
Q-100530
jyperin
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4h-chromen-3-yl hexopyranoside #
OVSQVDMCBVZWGM-DTGCRPNFSA-N
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
3,3',4',5,7-pentahydroxyflavone 3-d-galactoside
mfcd00016933
quercetin 3-b-d-galactoside
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4h-chromen-4-one
hyperoside, united states pharmacopeia (usp) reference standard
hyperoside, primary pharmaceutical reference standard
3-o-b-d-galactopyranosyloxy-3',4',5,7-tetrahydroxyflavone
quercetin 3-o-beta-d-galactoside
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yloxy)-4h-chromen-4-one
HY-N0452
CS-0008982
Q5242815
3-((2s,3r,4s,5r,6r)-3,4,5-trihydroxy-
2-yloxy)-4h-chromen-4-one
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
6-(hydroxymethyl)tetrahydro-2h-pyran-
hyperin,(s)
jm5b01461, compound 84
bdbm429266
AS-56199
NCGC00168902-03
J6O ,
2-[3,4-bis(oxidanyl)phenyl]-3-[(2s,3r,4s,5r,6r)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5,7-bis(oxidanyl)chromen-4-one
DTXSID501028789
2-(3,4-dihydroxyphenyl)-3-(alpha-d-galactopyranosyloxy)-5,7-dihydroxy-4h-1-benzopyran-4-one
hyperoside (usp-rs)
hyperoside (constituent of st. john's wort)
hyperoside (constituent of hawthorn leaf with flower)

Research Excerpts

Overview

Hyperoside (Hyp) is a flavonoid active compound deriving from Chinese herbal medicines. Hyperoside is a natural flavonol glycoside in various plants, such as Crataegus pinnatifida Bge.

ExcerptReferenceRelevance
"Hyperoside (Hyp) is a flavonol glycoside compound with antioxidant and anti-apoptotic properties."( Hyperoside Attenuates Zearalenone-induced spleen injury by suppressing oxidative stress and inhibiting apoptosis in mice.
Ge, M; Li, X; Shi, G; Sun, J; Tai, T; Wang, J; Wang, P; Wang, Y; Zhu, W, 2022
)
2.89
"Hyperoside (Hyp) is a flavonoid active compound deriving from Chinese herbal medicines. "( Hyperoside exerts osteoprotective effect on dexamethasone-induced osteoblasts by targeting NADPH Oxidase 4 (NOX4) to inhibit the reactive oxygen species (ROS) accumulation and activate c-Jun N-terminal kinase (JNK) pathway.
Fan, S; Huang, J; Lei, Z; Liu, J; Pan, H, 2022
)
3.61
"Hyperoside is a natural flavonol glycoside in various plants, such as Crataegus pinnatifida Bge, Forsythia suspensa, and Cuscuta chinensis Lam. "( Hyperoside: A review on its sources, biological activities, and molecular mechanisms.
Li, Y; Wan, XH; Wang, Q; Wei, HC; Zheng, TT; Zhou, CZ; Zhou, SJ, 2022
)
3.61
"Hyperoside is an active ingredient in plants, such as "( Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity.
Chen, S; Fu, X; Sui, H; Xia, W; Xu, S, 2022
)
3.61
"Hyperoside is an active flavonoid glycoside that exhibits anti‑inflammation, anti‑oxidation and anti‑apoptosis effects."( Hyperoside ameliorates TNF‑α‑induced inflammation, ECM degradation and ER stress‑mediated apoptosis via the SIRT1/NF‑κB and Nrf2/ARE signaling pathways
Li, P; Mei, L; Pan, R; Xie, T; Yuan, J, 2022
)
2.89
"Hyperoside is a flavonoid glycoside compound and exerts anti-inflammation, and anti-tumor growth properties."( Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling.
Li, M; Liu, Y; Piao, H; Sun, T; Yu, H, 2020
)
1.6
"Hyperoside (HYP) is a flavanone glycoside reported to possess diverse pharmacological benefits such as antioxidant and anti-inflammatory properties."( Hyperoside attenuates neuroinflammation, cognitive impairment and oxidative stress via suppressing TNF-α/NF-κB/caspase-3 signaling in type 2 diabetes rats.
Chen, X; Famurewa, AC; Olatunde, OO; Olatunji, OJ; Tang, J, 2022
)
2.89
"Hyperoside (Hyp) is a flavonoid, showing significant anti-inflammatory effects."( Hyperoside prevents sepsis-associated cardiac dysfunction through regulating cardiomyocyte viability and inflammation via inhibiting miR-21.
Liu, L; Liu, Y; Zhang, J, 2021
)
2.79
"Hyperoside is a major active constituent in many medicinal plants traditionally used in Chinese medicines for their anti-inflammatory, antioxidative, and vascular protective effects. "( Hyperoside inhibits the effects induced by oxidized low-density lipoprotein in vascular smooth muscle cells via oxLDL-LOX-1-ERK pathway.
Chen, Z; Du, B; Zhang, D; Zhang, Z, 2017
)
3.34
"Hyperoside (HY) is a major pharmacologically active component from Prunella vulgaris L. "( Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism.
Li, Z; Sun, Y; Tantai, J; Yang, Y; Zhong, C, 2017
)
2.3
"Hyperoside is a major bioactive component in Zanthoxylum bungeanum leaves (HZL) and is a natural antioxidant."( Anti-hypoglycemic and hepatocyte-protective effects of hyperoside from Zanthoxylum bungeanum leaves in mice with high-carbohydrate/high-fat diet and alloxan-induced diabetes.
Dong, H; Wang, M; Yu, X; Zhang, J; Zhang, Y, 2018
)
1.45
"Hyperoside (Hyp) is a flavonol glycoside extracted from medicinal plants and appears to exhibit potent antioxidant activity in various cells."( Hyperoside protects human kidney‑2 cells against oxidative damage induced by oxalic acid.
Chen, Y; Li, D; Li, F; Li, W; Ye, L, 2018
)
2.64
"Hyperoside (HPS) is a plant-derived quercetin 3-d-galactoside reported to have anti-inflammatory, anti-oxidant, anti-cancer, anti-hyperglycemic, anti-coagulant, and cardioprotective activities."( Hyperoside suppresses tumor necrosis factor α-mediated vascular inflammatory responses by downregulating mitogen-activated protein kinases and nuclear factor-κB signaling.
Jang, SA; Kang, SC; Lee, SR; Park, DW; Sohn, EH, 2018
)
2.64
"Hyperoside is an active constituent in the flowers of"( Protective effect of hyperoside against renal ischemia-reperfusion injury
An, X; Huang, Z; Li, Q; Liu, S; Wu, L; Xing, C; Yuan, Y; Zhang, B, 2019
)
1.55
"Hyperoside is a natural flavonoid that possesses anti-oxidant activity."( Hyperoside protects rat ovarian granulosa cells against hydrogen peroxide-induced injury by sonic hedgehog signaling pathway.
Bu, Y; Fan, G; Huang, W; Wang, X; Wei, F, 2019
)
2.68
"Hyperoside is a major active constituent in many medicinal plants which are traditionally used in Chinese medicines for their neuroprotective, anti-inflammatory and anti-oxidative effects. "( Identification of the major metabolites of hyperoside produced by the human intestinal bacteria using the ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry.
Duan, JA; Guo, J; Jiang, S; Qian, D; Shang, EX; Xu, J; Yang, J, 2013
)
2.1
"Hyperoside is a major active constituent in many medicinal plants which are traditionally used in Chinese medicines for their neuroprotective, anti-inflammatory and antioxidative effects. "( Hyperoside downregulates the receptor for advanced glycation end products (RAGE) and promotes proliferation in ECV304 cells via the c-Jun N-terminal kinases (JNK) pathway following stimulation by advanced glycation end-products in vitro.
Liao, S; Sethiel, MS; Shen, W; Zhang, Z; Zou, Y, 2013
)
3.28
"Hyperoside is an active compound isolated from Rhododendron brachycarpum G."( Anti-inflammatory effects of hyperoside in human endothelial cells and in mice.
Bae, JS; Han, MS; Ku, SK; Lee, W; Na, M; Zhou, W, 2015
)
1.43
"Hyperoside is a flavonol glycoside mainly found in plants of the genera Hypericum and Crataegus, which has shown anti-oxidant, anti-cancer and anti-inflammatory activities. "( Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis.
Gao, W; Jin, XN; Jin, Y; Liu, Z; Sui, HJ; Wang, HM; Yan, EZ, 2016
)
3.32
"Hyperoside (Hyp) is a flavonoid compound isolated from a folk remedy, Rhododendron ponticum L. "( Anti-apoptotic effects of hyperoside via inhibition of NR2B-containing NMDA receptors.
Feng, B; Guo, YY; Li, JM; Liu, SB; Xu, ZH; Yang, Q; Zhang, XN; Zhao, MG,
)
1.87
"Hyperoside (Hyp) is a flavonoid compound isolated from Rhododendron ponticum L. "( Protective effects of hyperoside against human umbilical vein endothelial cell damage induced by hydrogen peroxide.
Hu, J; Li, XQ; Li, ZL; Liu, JC; Wang, SW; Yi, DH; Zhao, MG, 2012
)
2.14
"Hyperoside is a flavonoid compound and widely used in clinic to relieve pain and improve cardiovascular functions. "( Hyperoside protects cortical neurons from oxygen-glucose deprivation-reperfusion induced injury via nitric oxide signal pathway.
Chen, JG; Cheng, J; Fu, H; Hu, ZL; Liu, RL; Shu, Q; Wang, F; Wu, WN; Xiong, QJ, 2012
)
3.26

Effects

Hyperoside has a variety of pharmacological activities, including anti-liver injury, anti-depression, and anti-inflammatory. It also has anti-cancer activities.

Hyperoside (HYP) has various potential benefits, however, its low water-solubility and poor bioavailability have restricted its application. Hyperoside has been reported to exert protective effect on liver injury and fibrosis.

ExcerptReferenceRelevance
"Hyperoside has a protective effect on hepatic IR injury in rats, which may be due to its antioxidant and antiapoptotic properties."( Hyperoside Attenuates Hepatic Ischemia-Reperfusion Injury by Suppressing Oxidative Stress and Inhibiting Apoptosis in Rats.
Dai, M; Jin, G; Qiu, X; Shi, Y; Zhang, X,
)
3.02
"Hyperoside has a variety of pharmacological activities, including anti-liver injury, anti-depression, anti-inflammatory, and anti-cancer activities. "( Hyperoside Reduces Rotenone-induced Neuronal Injury by Suppressing Autophagy.
Chai, Z; Fan, H; Jin, X; Li, Y; Ma, C; Song, L; Sun, M; Wang, Q; Xiao, W; Yu, J; Zhang, B, 2021
)
3.51
"Hyperoside has a protective effect on hepatic IR injury in rats, which may be due to its antioxidant and antiapoptotic properties."( Hyperoside Attenuates Hepatic Ischemia-Reperfusion Injury by Suppressing Oxidative Stress and Inhibiting Apoptosis in Rats.
Dai, M; Jin, G; Qiu, X; Shi, Y; Zhang, X,
)
3.02
"Hyperoside has been widely reported to ameliorate diabetes-associated disease."( Hyperoside ameliorates diabetic nephropathy induced by STZ via targeting the miR-499-5p/APC axis.
Bao, J; Lou, Y; Sun, X; Yu, J; Zhang, S; Zhou, J, 2021
)
2.79
"Hyperoside (HYP) has various potential benefits, however, its low water-solubility and poor bioavailability have restricted its application. "( Fabrication and characterization of zein-tea polyphenols-pectin ternary complex nanoparticles as an effective hyperoside delivery system: Formation mechanism, physicochemical stability, and in vitro release property.
Jin, Y; Li, F; Li, M; Liu, F; Lou, X; Peng, F; Wang, J; Wang, X; Xu, H, 2021
)
2.28
"Hyperoside has a variety of pharmacological activities, including anti-liver injury, anti-depression, anti-inflammatory, and anti-cancer activities. "( Hyperoside Reduces Rotenone-induced Neuronal Injury by Suppressing Autophagy.
Chai, Z; Fan, H; Jin, X; Li, Y; Ma, C; Song, L; Sun, M; Wang, Q; Xiao, W; Yu, J; Zhang, B, 2021
)
3.51
"Hyperoside has been reported to exert protective effect on liver injury and fibrosis."( Hyperoside protects against heart failure-induced liver fibrosis in rats.
Ge, Y; Guo, X; Jiang, X; Liu, X; Zhao, W; Zhu, C, 2019
)
2.68
"Hyperoside has been documented as having anti-inflammatory and diurectic properties, whereas quercitrin may play a role in intestinal repair following chronic mucosal injury."( Extraction of hyperoside and quercitrin from mimosa (Albizia julibrissin) foliage.
Bransby, DI; Carrier, DJ; Clausen, EC; Duan, L; Ekenseair, AK, 2006
)
1.42

Actions

ExcerptReferenceRelevance
"Hyperoside was found to inhibit H2O2-induced apoptosis in Chinese hamster lung fibroblast (V79-4) cells, as shown by decreased apoptotic nuclear fragmentation, decreased sub-G(1) cell population, and decreased DNA fragmentation."( Hyperoside prevents oxidative damage induced by hydrogen peroxide in lung fibroblast cells via an antioxidant effect.
Hyun, JW; Kang, KA; Kang, SS; Kim, HS; Kim, JS; Ko, DO; Piao, MJ; Wang, ZH; You, HJ; Zhang, R, 2008
)
2.51

Treatment

Hyperoside treatment in ACF rats increased cardiac output, the maximum peak rate of rise/fall in left ventricular pressure and LV ejection fraction. Co-treatment with hyperoside diminished follicular depletion of the primordial follicles, decreased follicular atresia and prevented Cy-induced excessive hypoxia.

ExcerptReferenceRelevance
"Hyperoside treatment also decreased the activity of malondialdehyde, increased the activities of superoxide dismutase and glutathione peroxidase, up-regulated the expression of heme oxygenase 1 and NAD(P)H:quinone oxidoreductase 1, and reduced the apoptotic index after IR injury."( Hyperoside Attenuates Hepatic Ischemia-Reperfusion Injury by Suppressing Oxidative Stress and Inhibiting Apoptosis in Rats.
Dai, M; Jin, G; Qiu, X; Shi, Y; Zhang, X,
)
2.3
"Hyperoside treatment improved cardiac function, decreased cardiomyocyte cross-sectional area and heart weight to body weight (HW/BW) ratio in HF rats."( Protective effect of hyperoside on heart failure rats via attenuating myocardial apoptosis and inducing autophagy.
Guo, X; Jiang, X; Lu, C; Qu, F; Zhang, Y, 2020
)
1.6
"Hyperoside treatment in ACF rats increased cardiac output, the maximum peak rate of rise/fall in left ventricular pressure (+dP/dt, -dP/dt) and LV ejection fraction (LVEF), decreased LV end-systolic pressure (LVESP), LV end-diastolic pressure (LVEDP) and LV end-systolic volume (LVESV), and reduced heart weight/body weight ratio in a dose-dependent manner."( Hyperoside protects against heart failure-induced liver fibrosis in rats.
Ge, Y; Guo, X; Jiang, X; Liu, X; Zhao, W; Zhu, C, 2019
)
2.68
"Co-treatment with hyperoside diminished follicular depletion of the primordial follicles, decreased follicular atresia, prevented Cy-induced excessive hypoxia and autophagy activation, increased mitochondrial membrane potential, thereby increasing follicular reserve and rescuing fertility in Cy-treated mice."( Hyperoside protects against cyclophosphamide induced ovarian damage and reduced fertility by suppressing HIF-1α/BNIP3-mediated autophagy.
Deng, G; Gao, J; Lai, Y; Ruan, X; Zeng, F; Zhu, F, 2022
)
2.49
"Treatment with hyperoside significantly improved sperm density, sperm viability and testicular function compared to untreated oligoasthenozoospermia mice."( Studying the effect of hyperoside on recovery from cyclophosphamide induced oligoasthenozoospermia.
Fan, Q; Gao, P; He, R; Huang, R; Li, H; Li, R; Li, Y; Liang, X; Zhang, J, 2023
)
1.56
"Pretreatment with hyperoside protected the liver from IR injury by a reduction in serum aspartate aminotransferase/alanine aminotransferase levels and a decrease in the severity of histologic changes. "( Hyperoside Attenuates Hepatic Ischemia-Reperfusion Injury by Suppressing Oxidative Stress and Inhibiting Apoptosis in Rats.
Dai, M; Jin, G; Qiu, X; Shi, Y; Zhang, X,
)
1.91
"Treatment with hyperoside (40 mg/kg) improved pregnancy outcome manifest as increasing the weight of fetuses and decreasing the fetal resorption rate. "( Hyperoside attenuates pregnancy loss through activating autophagy and suppressing inflammation in a rat model.
Li, H; Ni, T; Ren, X; Song, Y; Wan, Y; Wei, A; Xiao, H; Xu, G, 2020
)
2.35
"Pre-treatment with hyperoside (30 mg/kg/d) for four weeks could significantly decrease albuminuria, prevent GBM damage and oxidative stress in diabetes mellitus (DM) mice."( Hyperoside pre-treatment prevents glomerular basement membrane damage in diabetic nephropathy by inhibiting podocyte heparanase expression.
An, X; He, M; Li, L; Wang, B; Yao, Q; Yuan, Y; Zhang, J; Zhang, L, 2017
)
2.22
"Treatment of hyperoside also inhibited OVA-induced airway hyperresponsiveness (AHR)."( Hyperoside attenuates OVA-induced allergic airway inflammation by activating Nrf2.
Chen, X; Shi, C; Yang, XL; Ye, P, 2017
)
2.25

Toxicity

ExcerptReferenceRelevance
" It is obvious that hawthorn, particularly flavonoids constituents with antioxidative activity, reduced the oxidative stress and genotoxicity induced by toxic compounds."( Protective effect of hawthorn extract against genotoxicity induced by methyl methanesulfonate in human lymphocytes.
Azadbakht, M; Hosseinimehr, SJ; Mahmodzadeh, A; Mohammadifar, S; Tanha, M, 2011
)
0.37
"To observe the toxicity of hyperoside in rat embryo-fetal development, in order to provide preference for safe use of drugs during gestation period."( [Study on toxicity of hyperoside in rat embryo-fetal development].
Ai, G; Huang, Z; Liu, Z; Wang, D, 2012
)
0.99

Pharmacokinetics

The study was designed to find out whether the improved water solubility in the presence of procyanidin B2 or hyperoside is correlated to increased plasma levels of hypericin.

ExcerptReferenceRelevance
" The present pharmacokinetic study was designed to find out whether the improved water solubility in the presence of procyanidin B2 or hyperoside is correlated to increased plasma levels of hypericin."( Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.
Butterweck, V; Liefländer-Wulf, U; Nahrstedt, A; Winterhoff, H, 2003
)
0.76
"A simple and specific high-performance liquid chromatographic (HPLC) method was developed for the pharmacokinetic study of hyperoside (HP, isolated from the leaves of Crataegus pinnatifida Bge."( LC determination and pharmacokinetic study of hyperoside in rat plasma after intravenous administration.
Kang, TG; Liu, X; Meng, XS; Wang, D; Wang, SY; Ying, XX; Zhang, WJ, 2010
)
0.83
" The validated method has been successfully applied to pharmacokinetic studies of the three analytes following intragastric administration of Eupatorium lindleyanum extract at a single dose of 100, 250, and 625mg/kg to Sprague-Dawley rats, respectively."( Pharmacokinetics of eupalinolide A, eupalinolide B and hyperoside from Eupatorium lindleyanum in rats by LC/MS/MS.
Lu, X; Yu, X; Zhang, J; Zhao, F; Zheng, G, 2015
)
0.66
" Pretreatment with verapamil increased the peak concentration and area under the concentration-time curve of hyperin, which were significantly higher than the control values."( Simultaneous quantification of hyperin, reynoutrin and guaijaverin in mice plasma by LC-MS/MS: application to a pharmacokinetic study.
Guo, J; Li, Z; Meng, F; Peng, S; Sun, L; Yu, L; Zhang, Y; Zhang, Z, 2016
)
0.43
" The pharmacokinetic characteristics of Hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex in rats were evaluated."( Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated DSS-induced colitis in mice.
Cao, S; Chu, X; Ding, Y; Fu, X; Li, X; Li, Y; Liu, C; Su, J; Wang, X; Xue, J; Zhang, R; Zhang, X, 2023
)
1.47

Compound-Compound Interactions

ExcerptReferenceRelevance
"Previous research found Potentilla fruticosa leaf extracts (PFE) combined with green tea polyphenols (GTP) showed obvious synergistic effects based on chemical mechanisms."( Synergistic effects and related bioactive mechanisms of Potentilla fruticosa Linn. leaves combined with green tea polyphenols studied with microbial test system (MTS).
Ji, X; Li, DW; Liu, ZH; Luo, ZW; Wang, DM, 2018
)
0.48

Bioavailability

Hyperoside has various potential benefits, but its low water-solubility and poor bioavailability have restricted its application. The aim of this study was to develop hyperoside (Hyp) nanocrystals to enhance its dissolution rate, oral bioavailability and anti-HBV activity.

ExcerptReferenceRelevance
" Both compounds increased the oral bioavailability of hypericin by ca."( Plasma levels of hypericin in presence of procyanidin B2 and hyperoside: a pharmacokinetic study in rats.
Butterweck, V; Liefländer-Wulf, U; Nahrstedt, A; Winterhoff, H, 2003
)
0.56
" The poor bioavailability of important dietary quercetin glycosides has implications for their in vivo bioactivities."( The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides.
Arts, IC; Faassen-Peters, M; Hollman, PC; Sesink, AL, 2004
)
0.32
" Co-effectors in the extract improve the bioavailability of active constituents such as hypericin (1) (pharmacokinetic synergy)."( Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
Butterweck, V; Nahrstedt, A, 2010
)
0.36
" The absorption rate of flavonoid glycoside was lower than that of aglycone; the flavonoids from Abelmoschus manihot flowers could be absorbed in all of the intestinal segments."( [Absorption of flavonoids from Abelmoschus manihot extract by in situ intestinal perfusion].
Duan, JA; Guo, JM; Qian, DW; Shu, Y; Xue, CF, 2011
)
0.37
") should be further investigated and be explored to obtain higher bioavailability and better activity for hyperoside."( Application of microdialysis for elucidating the existing form of hyperoside in rat brain: comparison between intragastric and intraperitoneal administration.
Duan, JA; Guo, JM; Lin, P; Qian, DW; Shang, EX; Tang, YP, 2012
)
0.83
"The aim of this study was to develop hyperoside (Hyp) nanocrystals to enhance its dissolution rate, oral bioavailability and anti-HBV activity."( Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation.
Han, J; Lu, Y; Shen, B; Shen, C; Wang, Y; Wu, N; Wu, W; Wu, Y; Xu, P; Yuan, H; Zhang, F; Zhang, L, 2016
)
2.15
" Also the ability of each classification system to predict and determine the extent of absorption of the Chinese herbal compound was investigated based on the absolute bioavailability of representative components."( Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet).
Cao, X; Dou, Z; Li, H; Liu, T; Liu, Y; Ren, X; Wang, M, 2019
)
0.51
" Nuciferine is the best of the five components, with absolute bioavailability reaching 61."( Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet).
Cao, X; Dou, Z; Li, H; Liu, T; Liu, Y; Ren, X; Wang, M, 2019
)
0.51
"The five representative components (except for nuciferine) are all class III/IV, which correlates well with the absolute bioavailability results and demonstrates that they are poorly absorbed substances."( Establishment of modified biopharmaceutics classification system absorption model for oral Traditional Chinese Medicine (Sanye Tablet).
Cao, X; Dou, Z; Li, H; Liu, T; Liu, Y; Ren, X; Wang, M, 2019
)
0.51
"Hyperoside (HYP) has various potential benefits, however, its low water-solubility and poor bioavailability have restricted its application."( Fabrication and characterization of zein-tea polyphenols-pectin ternary complex nanoparticles as an effective hyperoside delivery system: Formation mechanism, physicochemical stability, and in vitro release property.
Jin, Y; Li, F; Li, M; Liu, F; Lou, X; Peng, F; Wang, J; Wang, X; Xu, H, 2021
)
2.28
"An inclusion complex formation with cyclodextrin is a promising method to improve the bioavailability of water-insoluble drugs."( Pharmacokinetic studies of hyperoside-2-hydroxypropyl-β-cyclodextrin inclusion complex and ameliorated DSS-induced colitis in mice.
Cao, S; Chu, X; Ding, Y; Fu, X; Li, X; Li, Y; Liu, C; Su, J; Wang, X; Xue, J; Zhang, R; Zhang, X, 2023
)
1.21

Dosage Studied

ExcerptRelevanceReference
"10 g x kg(-1) x d(-1) dosage groups of hyperoside (P<0."( In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik.
Huang, ZM; Liu, HZ; Wu, GX; Wu, LL; Yang, XB, 2007
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
hepatoprotective agentAny compound that is able to prevent damage to the liver.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
beta-D-galactosideAny D-galactoside having beta-configuration at its anomeric centre.
quercetin O-glycosideAny glycosyloxyflavone that is an O-glycosylated derivative of quercetin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency5.01190.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency7.92450.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency1.77830.177814.390939.8107AID2147
Microtubule-associated protein tauHomo sapiens (human)Potency31.62280.180013.557439.8107AID1460
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
alpha-galactosidaseHomo sapiens (human)Potency35.48134.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency12.58930.035520.977089.1251AID504332
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency20.89550.036619.637650.1187AID2100; AID2112
DNA polymerase betaHomo sapiens (human)Potency5.01190.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID1454
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency28.18380.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency28.18380.891312.067628.1838AID1487
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency6.74560.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)50.50000.00403.43889.5100AID1805532
NeuraminidaseInfluenza A virus (A/USSR/90/1977(H1N1))IC50 (µMol)74.00000.00140.00550.0130AID1186763; AID1186764
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)42.70000.03002.29719.5100AID1804126
Replicase polyprotein 1abHuman coronavirus 229EIC50 (µMol)42.70000.03002.14419.5100AID1804126
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)46.60000.00402.92669.9600AID1804126; AID1805532
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)50.50000.00022.45859.9600AID1805532
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)1.20000.00002.015110.0000AID1820779
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)3.00000.00101.191310.0000AID639825
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)21.76000.00000.54509.1000AID1126472
Cyclin-dependent-like kinase 5 Homo sapiens (human)IC50 (µMol)10.28000.00021.183210.0000AID767308
2-5A-dependent ribonucleaseHomo sapiens (human)IC50 (µMol)1.43251.32001.43251.6300AID1820767; AID1820773; AID1820774; AID1820775
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)IC50 (µMol)10.28000.00101.289810.0000AID767308
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)Ke0.39000.00000.24883.0700AID311281
Delta-type opioid receptorHomo sapiens (human)Ke9.07000.00010.69799.0700AID311282
Kappa-type opioid receptorHomo sapiens (human)Ke0.34000.00000.35405.8100AID311280
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (172)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, dopaminergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
intracellular protein transportCyclin-dependent-like kinase 5 Homo sapiens (human)
cell-matrix adhesionCyclin-dependent-like kinase 5 Homo sapiens (human)
chemical synaptic transmissionCyclin-dependent-like kinase 5 Homo sapiens (human)
synapse assemblyCyclin-dependent-like kinase 5 Homo sapiens (human)
skeletal muscle tissue developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
motor neuron axon guidanceCyclin-dependent-like kinase 5 Homo sapiens (human)
visual learningCyclin-dependent-like kinase 5 Homo sapiens (human)
Schwann cell developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of macroautophagyCyclin-dependent-like kinase 5 Homo sapiens (human)
phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
sensory perception of painCyclin-dependent-like kinase 5 Homo sapiens (human)
cerebellar cortex formationCyclin-dependent-like kinase 5 Homo sapiens (human)
hippocampus developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent-like kinase 5 Homo sapiens (human)
central nervous system neuron developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
corpus callosum developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projection developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein ubiquitinationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor catabolic processCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein localization to synapseCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor clusteringCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of proteolysisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein export from nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
behavioral response to cocaineCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle endocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
rhythmic processCyclin-dependent-like kinase 5 Homo sapiens (human)
axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
oligodendrocyte differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
dendrite morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
cell divisionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
excitatory postsynaptic potentialCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
calcium ion importCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of protein localization to plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic vesicle recyclingCyclin-dependent-like kinase 5 Homo sapiens (human)
cellular response to amyloid-betaCyclin-dependent-like kinase 5 Homo sapiens (human)
axonogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle transportCyclin-dependent-like kinase 5 Homo sapiens (human)
rRNA processing2-5A-dependent ribonucleaseHomo sapiens (human)
mRNA processing2-5A-dependent ribonucleaseHomo sapiens (human)
protein phosphorylation2-5A-dependent ribonucleaseHomo sapiens (human)
regulation of mRNA stability2-5A-dependent ribonucleaseHomo sapiens (human)
negative regulation of viral genome replication2-5A-dependent ribonucleaseHomo sapiens (human)
fat cell differentiation2-5A-dependent ribonucleaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase II2-5A-dependent ribonucleaseHomo sapiens (human)
positive regulation of glucose import2-5A-dependent ribonucleaseHomo sapiens (human)
defense response to virus2-5A-dependent ribonucleaseHomo sapiens (human)
RNA processing2-5A-dependent ribonucleaseHomo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron migrationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron cell-cell adhesionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayCyclin-dependent kinase 5 activator 1Homo sapiens (human)
axon guidanceCyclin-dependent kinase 5 activator 1Homo sapiens (human)
axonal fasciculationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
brain developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
embryo development ending in birth or egg hatchingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of macroautophagyCyclin-dependent kinase 5 activator 1Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cerebellum developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
superior olivary nucleus maturationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
hippocampus developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron differentiationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of microtubule polymerizationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron projection developmentCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of actin cytoskeleton organizationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of neuron differentiationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ephrin receptor signaling pathwayCyclin-dependent kinase 5 activator 1Homo sapiens (human)
rhythmic processCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent kinase 5 activator 1Homo sapiens (human)
G1 to G0 transition involved in cell differentiationCyclin-dependent kinase 5 activator 1Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
regulation of synaptic vesicle cycleCyclin-dependent kinase 5 activator 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (81)

Processvia Protein(s)Taxonomy
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
microtubule bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
p53 bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-2 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
ATP bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
acetylcholine receptor activator activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-3 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau-protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
Hsp90 protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
RNA binding2-5A-dependent ribonucleaseHomo sapiens (human)
RNA endonuclease activity2-5A-dependent ribonucleaseHomo sapiens (human)
RNA nuclease activity2-5A-dependent ribonucleaseHomo sapiens (human)
protein kinase activity2-5A-dependent ribonucleaseHomo sapiens (human)
protein binding2-5A-dependent ribonucleaseHomo sapiens (human)
ATP binding2-5A-dependent ribonucleaseHomo sapiens (human)
rRNA binding2-5A-dependent ribonucleaseHomo sapiens (human)
ribonucleoprotein complex binding2-5A-dependent ribonucleaseHomo sapiens (human)
metal ion binding2-5A-dependent ribonucleaseHomo sapiens (human)
protease bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
calcium ion bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
kinase activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase activator activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ionotropic glutamate receptor bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
alpha-tubulin bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein serine/threonine kinase activator activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cadherin bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
ephrin receptor bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
beta-tubulin bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
actin filament bindingCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
microtubuleCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytosolCyclin-dependent-like kinase 5 Homo sapiens (human)
plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
postsynaptic densityCyclin-dependent-like kinase 5 Homo sapiens (human)
membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase 5 complexCyclin-dependent-like kinase 5 Homo sapiens (human)
lamellipodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
cell junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
filopodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
axonCyclin-dependent-like kinase 5 Homo sapiens (human)
dendriteCyclin-dependent-like kinase 5 Homo sapiens (human)
growth coneCyclin-dependent-like kinase 5 Homo sapiens (human)
neuromuscular junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projectionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuronal cell bodyCyclin-dependent-like kinase 5 Homo sapiens (human)
perikaryonCyclin-dependent-like kinase 5 Homo sapiens (human)
presynapseCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cellular_component2-5A-dependent ribonucleaseHomo sapiens (human)
mitochondrial matrix2-5A-dependent ribonucleaseHomo sapiens (human)
cytosol2-5A-dependent ribonucleaseHomo sapiens (human)
nuclear matrix2-5A-dependent ribonucleaseHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 5 activator 1Homo sapiens (human)
nucleusCyclin-dependent kinase 5 activator 1Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytosolCyclin-dependent kinase 5 activator 1Homo sapiens (human)
plasma membraneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
postsynaptic densityCyclin-dependent kinase 5 activator 1Homo sapiens (human)
membraneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
protein kinase 5 complexCyclin-dependent kinase 5 activator 1Homo sapiens (human)
axonCyclin-dependent kinase 5 activator 1Homo sapiens (human)
dendriteCyclin-dependent kinase 5 activator 1Homo sapiens (human)
growth coneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuromuscular junctionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuron projectionCyclin-dependent kinase 5 activator 1Homo sapiens (human)
neuronal cell bodyCyclin-dependent kinase 5 activator 1Homo sapiens (human)
dendritic spineCyclin-dependent kinase 5 activator 1Homo sapiens (human)
perikaryonCyclin-dependent kinase 5 activator 1Homo sapiens (human)
intracellular membrane-bounded organelleCyclin-dependent kinase 5 activator 1Homo sapiens (human)
contractile muscle fiberCyclin-dependent kinase 5 activator 1Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
presynapseCyclin-dependent kinase 5 activator 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 5 activator 1Homo sapiens (human)
growth coneCyclin-dependent kinase 5 activator 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (141)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1323132Antioxidant activity assessed as DPPH free radical scavenging activity by measuring remaining DPPH at 5 uM after 15 to 60 mins relative to trolox2016Journal of natural products, 07-22, Volume: 79, Issue:7
Effects of Functional Groups and Sugar Composition of Quercetin Derivatives on Their Radical Scavenging Properties.
AID639825Inhibition of human recombinant aldose reductase using D-glyceraldehyde as substrate preincubated for 10 mins before substrate addition measured for every 10 secs for 50 mins by spectrophotometry2012Bioorganic & medicinal chemistry, Feb-01, Volume: 20, Issue:3
Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase.
AID339129Inhibition of collagen-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID1126474Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM after 18 hrs by griess reaction analysis2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1126472Inhibition of sEH (unknown origin) assessed as substrate PHOME hydrolysis after 1 hr by fluorescence method2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID687510Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as increase in CCL-induced nuclear Nrf2 protein level at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western 2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID687527Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum ALT level at 50 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 10229 +/- 918 U/L)2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID603461Inhibition of Escherichia coli DNA gyrase assessed as inhibition of pBR322 supercoiling by densitometry2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID311282Antagonist activity at human delta opioid receptor expressed in CHO cells by [35S]GTPgammaS assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID578843Cytotoxicity against human A2780 cells assessed as intracellular ATP level at 10 uM after 72 hrs by luminometry2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1126475Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 0.4 uM after 18 hrs by griess reaction analysis2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID1323133Antioxidant activity assessed as DPPH free radical scavenging activity at 5 uM after 15 to 60 mins in presence of CuSO4.5H2O2016Journal of natural products, 07-22, Volume: 79, Issue:7
Effects of Functional Groups and Sugar Composition of Quercetin Derivatives on Their Radical Scavenging Properties.
AID1820776Inhibition of wild type P-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1327604Inhibition of hog pancreas alpha-amylase using starch as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by dinitrosalicylic acid color reagent-based UV-Vis spectrophotometric analysis2016Journal of natural products, 08-26, Volume: 79, Issue:8
α-Glucosidase and α-Amylase Inhibitors from Arcytophyllum thymifolium.
AID687506Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced COX2 protein expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western bl2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1126471Inhibition of sEH (unknown origin) assessed as substrate PHOME hydrolysis at 25 uM after 1 hr by fluorescence method2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID1126477Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion at 0.4 uM after 18 hrs by sandwich ELISA2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID578760Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1257226Inhibition of Trichomonas vaginalis uridine ribohydrolase after 40 mins2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Adenosine/guanosine preferring nucleoside ribohydrolase is a distinct, druggable antitrichomonal target.
AID1168660Antiviral activity against Dengue virus assessed as inhibition of viral replication2014European journal of medicinal chemistry, Nov-24, Volume: 87A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
AID687519Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum MDA level per mg protein at 200 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by TBARS detection based spectr2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID603365Antibacterial activity against methicillin-resistant Staphylococcus aureus OM481 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID603363Antibacterial activity against vancomycin resistant Enterococcus NCTC 12201 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID379776Cytotoxicity against human MCF7 cells after 7 days by MTT method1999Journal of natural products, May, Volume: 62, Issue:5
Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium niveum.
AID603364Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID671762Inhibition of HCV NS3 helicase overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID1820775Inhibition of full length H-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 20 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID578759Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID403918Displacement of [3H]DPCPX from adenosine A1 receptor in rat forebrain membrane assessed as fraction of receptor bound radioligand at 100 ug/mL1997Journal of natural products, Jun, Volume: 60, Issue:6
Adenosine-1 active ligands: cirsimarin, a flavone glycoside from Microtea debilis.
AID603458Antibacterial activity against Pseudomonas aeruginosa PAO1 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1186765Inhibition of influenza B virus (B/Brisbane/60/2008) neuraminidase using MUNANA substrate pre-incubated for 30 mins before substrate addition by fluorometric assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
AID1820766Inhibition of recombinant full length P-RNAase L (1 to 743 residues)expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate in presence of 2-5A AND ATP/MgCl2 by STD-NMR spectroscopy2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID603368Antibacterial activity against methicillin-resistant Staphylococcus aureus COL after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID687526Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum ALT level at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 10229 +/- 918 U/L)2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID311284Selectivity for antagonist activity at human delta opioid receptor to kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID603475Antibacterial activity against methicillin-susceptible Staphylococcus aureus 209P after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1171178Cytotoxicity against human HCT116 cells at 1.25 to 20 uM after 96 hrs by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID339130Inhibition of platelet activity factor-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID687514Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in portal inflammation at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by hematoxylin-eosin staining2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1820771Inhibition of full length P-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 5 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID578844Cytotoxicity against human MCF7 cells assessed as intracellular ATP level at 10 uM after 72 hrs by luminometry2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID603367Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1186767Selectivity index, ratio of CC50 for MDCK cells to IC50 for influenza A virus (A/Perth/16/2009(H3N2))2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
AID478686Antidepressant activity in rat assessed as immobility time at 0.6 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1194986Antioxidant activity assessed as FRAP values at 100 ug/ml incubated at 37 degC for 5 mins by FeSO4.7H2O calibration curve based method2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID1194985Antioxidant activity assessed as FRAP values at 50 ug/ml incubated at 37 degC for 5 mins by FeSO4.7H2O calibration curve based method2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID379778Cytotoxicity against human A549 cells after 7 days by MTT method1999Journal of natural products, May, Volume: 62, Issue:5
Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium niveum.
AID578765Inhibition of P-gp expressed in A2780adr cells at 10 uM by calcein AM accumulation assay relative to verapamil2011Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
AID1194983Antioxidant activity assessed as FRAP values at 12.5 ug/ml incubated at 37 degC for 5 mins by FeSO4.7H2O calibration curve based method2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID1820780Suppression of 2-5A-induced full length P-RNase L oligomerization in presence of upto 2 uM 2-5A at 40 uM by SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1516973Antifungal activity against Cryptococcus neoformans after 48 hrs by broth micro dilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID381804Antiproliferative activity against human HL60 cells at 30 uM after 48 hrs by MTS assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects.
AID1516971Antifungal activity against Candida albicans after 48 hrs by broth micro dilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID379775Antiprotozoal activity against axenically grown trophozoites of Entamoeba histolytica HM1-IMSS after 48 hrs by MTT method1999Journal of natural products, May, Volume: 62, Issue:5
Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium niveum.
AID1820778Inhibition of RNAase L in human A549 cells assessed as rRNA cleavage pretreated at 30 uM for 4 hrs followed by treated with 20 uM 2-5A by Western blotting analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID687508Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced iNOS protein expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western bl2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID767308Inhibition of CDK5/p25 (unknown origin) after 30 mins by SDS-PAGE analysis2013Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18
Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.
AID339128Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID478687Antidepressant activity in rat assessed as immobility time at 1.3 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID380838Antioxidant activity assessed as DPPH free radical scavenging activity at 6 ug by TLC autographic assay1999Journal of natural products, Aug, Volume: 62, Issue:8
Phenylvaleric acid and flavonoid glycosides from Polygonum salicifolium.
AID1194984Antioxidant activity assessed as FRAP values at 25 ug/ml incubated at 37 degC for 5 mins by FeSO4.7H2O calibration curve based method2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID1820767Inhibition of recombinant full length H-RNAase L (1 to 741 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate in presence of 2-5A and ATP/MgCl2 by STD-NMR spectroscopy2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1126473Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 50 uM after 18 hrs by MTT assay in presence of LPS2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID687521Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum MDA level per mg protein at 50 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by TBARS detection based spectro2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID603366Antibacterial activity against methicillin-resistant Staphylococcus aureus OM584 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1239713Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 100 uM pre-incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition2015Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16
Potential therapeutic agents for circulatory diseases from Bauhinia glauca Benth.subsp. pernervosa. (Da Ye Guan Men).
AID1764181Hypolipidemic activity against oleic acid/palmitic acid-induced hyperlipidemia in human HepG2 cells assessed as reduction in triglycerides content2021Bioorganic & medicinal chemistry letters, 09-01, Volume: 47Phenolic compounds from the leaves of Crataegus pinnatifida Bge. var. major N.E.Br. And their lipid-lowering effects.
AID1194980Cytotoxicity against human HeLa cells by MTT assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID339146Inhibition of norepinephrine-induced Wistar rat thoracic aorta tonic contraction at 100 ug/mL after 15 mins1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID1820765Inhibition of P-RNAase L K164E mutant expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID687509Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced TNFalpha production at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by ELISA2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID339127Inhibition of ADP-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID687520Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum MDA level per mg protein at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by TBARS detection based spectr2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID687507Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced iNOS mRNA expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by RT-PCR2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1516972Antifungal activity against Candida parapsilosis after 48 hrs by broth micro dilution method2019Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19
Recent advances in natural antifungal flavonoids and their derivatives.
AID399391Inhibition of HIV1 recombinant integrase expressed in Escherichia coli1998Journal of natural products, Jan, Volume: 61, Issue:1
A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase.
AID1186766Cytotoxicity against MDCK cells2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
AID687515Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in centrizonal necrosis at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by hematoxylin-eosin stainin2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID380836Antioxidant activity assessed as DPPH free radical scavenging activity at 2 ug by TLC autographic assay1999Journal of natural products, Aug, Volume: 62, Issue:8
Phenylvaleric acid and flavonoid glycosides from Polygonum salicifolium.
AID687517Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum GSH level per gram of liver at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 4.8 +/- 0.3 umol/g li2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1126479Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs by sandwich ELISA2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID339142Inhibition of norepinephrine-induced Wistar rat thoracic aorta phasic contraction at 100 ug/mL after 15 mins1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID1126478Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID678057Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Antidiabetic compounds from Sarracenia purpurea used traditionally by the Eeyou Istchee Cree First Nation.
AID671764Inhibition of HCV NS3 helicase ATP hydrolysis activity overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of inorganic phosphate release by AM/MG-based colometric analysis in the presence of M13 ssDNA2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID379777Cytotoxicity against human HT-29 cells after 7 days by MTT method1999Journal of natural products, May, Volume: 62, Issue:5
Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium niveum.
AID311281Antagonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID603457Antibacterial activity against Streptococcus pneumoniae R6 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1820772Inhibition of full length P-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 20 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID1186763Inhibition of influenza A virus (A/California/07/2009(H1N1)) pdm09 neuraminidase using MUNANA substrate pre-incubated for 30 mins before substrate addition by fluorometric assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
AID379774Antiprotozoal activity against axenically grown trophozoites of Giardia lamblia IMSS:0989:1 after 48 hrs by MTT method1999Journal of natural products, May, Volume: 62, Issue:5
Geranins A and B, new antiprotozoal A-type proanthocyanidins from Geranium niveum.
AID311283Selectivity for antagonist activity at human mu opioid receptor to kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID311280Antagonist activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.
AID1194978Cytotoxicity against human SGC7901 cells by MTT assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID1195522Inhibition of PTP1B (unknown origin) at 20 ug/ml using pNPP substrate measured after 3 mins by colorimetric assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
PTP1B inhibitors from stems of Angelica keiskei (Ashitaba).
AID478690Antidepressant activity in rat assessed as immobility time at 7.6 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID603362Antibacterial activity against vancomycin resistant Enterococcus FN-1 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID671761Inhibition of SARS coronavirus nsP13 helicase activity expressed in Escherichia coli Rosetta assessed inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID603462Inhibition of Staphylococcus aureus DNA Topoisomerase 4-mediated decatenation of kDNA after 30 mins by densitometry2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID687513Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in Kupffer cell hyperplasia at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by hematoxylin-eosin sta2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1257224Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Adenosine/guanosine preferring nucleoside ribohydrolase is a distinct, druggable antitrichomonal target.
AID1820770Inhibition of full length P-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 1 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID380837Antioxidant activity assessed as DPPH free radical scavenging activity at 4 ug by TLC autographic assay1999Journal of natural products, Aug, Volume: 62, Issue:8
Phenylvaleric acid and flavonoid glycosides from Polygonum salicifolium.
AID687524Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum AST level at 50 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 7518 +/- 426 U/L)2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID687525Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum ALT level at 200 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 10229 +/- 918 U/L)2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID687518Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum GSH level per gram of liver at 50 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 4.8 +/- 0.3 umol/g liv2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID687512Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as augmentation of CCL-induced HO-1 protein expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by Western2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID478688Antidepressant activity in rat assessed as immobility time at 2.6 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID687516Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum GSH level per gram of liver at 200 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 4.8 +/- 0.3 umol/g li2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1126476Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion at 10 uM after 18 hrs by sandwich ELISA2014Bioorganic & medicinal chemistry letters, Apr-15, Volume: 24, Issue:8
Anti-inflammatory components of Euphorbia humifusa Willd.
AID380839Antioxidant activity assessed as DPPH free radical scavenging activity at 8 ug by TLC autographic assay1999Journal of natural products, Aug, Volume: 62, Issue:8
Phenylvaleric acid and flavonoid glycosides from Polygonum salicifolium.
AID1194979Cytotoxicity against human A549 cells by MTT assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID687528Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as reduction in CCL-induced COX2 mRNA expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by RT-PCR2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID603463Inhibition of Escherichia coli DNA topoisomerase 4 subunit ParC/DNA topoisomerase 4 subunit ParE-mediated decatenation of kDNA by densitometry2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID687522Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum AST level at 200 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 7518 +/- 426 U/L)2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1194981Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins by microplate reader based assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID1820777Inhibition of P-RNAase L R353E mutant expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID687523Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as serum AST level at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge (Rvb = 7518 +/- 426 U/L)2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1820773Inhibition of full length H-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 1 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID339141Inhibition of K(+)/Ca(2+)-induced Wistar rat thoracic aorta contraction at 100 ug/mL after 15 mins1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID678058Increase in glucose uptake in mouse C2C12 cells incubated for 18 hrs using [3H]-2-deoxy-D-glucose by liquid scintillation counting relative to DMSO2012Journal of natural products, Jul-27, Volume: 75, Issue:7
Antidiabetic compounds from Sarracenia purpurea used traditionally by the Eeyou Istchee Cree First Nation.
AID333525Cytotoxicity against human A549 cells at 20 mcg/mL after 3 days by SRB assay2004Journal of natural products, Nov, Volume: 67, Issue:11
Prenylated benzophenones and xanthones from Hypericum scabrum.
AID478689Antidepressant activity in rat assessed as immobility time at 5.2 mg/kg, po by forced swimming test (Rvb = 169.6 +/- 19 sec)2010Journal of natural products, May-28, Volume: 73, Issue:5
Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
AID1820774Inhibition of full length H-RNAase L expressed in Escherichia coli BL21 (DE3) assessed as inhibition rate incubated for 15 min in presence of 5 nM 2-5A for 15 mins by Coomassie staining based SDS-PAGE analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID687511Hepatoprotective activity against CCL4-induced liver damage in ICR mouse assessed as augmentation of CCL-induced HO-1 mRNA expression at 100 mg/kg, ip dosed 30 mins before and 2 hrs post CCL4 challenge and measured 24 hrs post CCL4 challenge by RT-PCR2011Journal of natural products, May-27, Volume: 74, Issue:5
Protective effects of hyperoside against carbon tetrachloride-induced liver damage in mice.
AID1257225Inhibition of Trichomonas vaginalis adenosine-guanosine preferring ribohydrolase after 40 mins in presence of 0.01% triton X-1002015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Adenosine/guanosine preferring nucleoside ribohydrolase is a distinct, druggable antitrichomonal target.
AID1186764Inhibition of influenza A virus (A/Perth/16/2009(H3N2)) neuraminidase using MUNANA substrate pre-incubated for 30 mins before substrate addition by fluorometric assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase.
AID603459Antibacterial activity against Escherichia coli K-12 after 24 hrs by microdilution method2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
AID1194982Antioxidant activity assessed as ABTS radical scavenging activity after 15 mins2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
Cytotoxic and antioxidant constituents from the leaves of Psidium guajava.
AID1820779Inhibition of human CYP2D6 preincubated for 5 min by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Identification of Small Molecule Inhibitors of RNase L by Fragment-Based Drug Discovery.
AID333526Cytotoxicity against human MCF7 cells at 20 mcg/mL after 3 days by SRB assay2004Journal of natural products, Nov, Volume: 67, Issue:11
Prenylated benzophenones and xanthones from Hypericum scabrum.
AID1171188Antitumor activity against human HCT116 cells xenografted in 48 hpf zebrafish embryo assessed as inhibition of cancer cell proliferation at 80 uM treated for 4 days2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1804126No assay is provided from Article 10.1021/acs.jmedchem.5b01461: \\An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.\\2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
AID1805532Various Assay from Article 10.1002/cmdc.202100576: \\A patent review on SARS coronavirus main protease (3CLpro) inhibitors.\\2022ChemMedChem, 01-05, Volume: 17, Issue:1
A Patent Review on SARS Coronavirus Main Protease (3CL
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (382)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (2.88)18.7374
1990's23 (6.02)18.2507
2000's66 (17.28)29.6817
2010's199 (52.09)24.3611
2020's83 (21.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.37 (24.57)
Research Supply Index5.98 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index69.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (2.28%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other385 (97.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]